Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Código da empresaEOLS
Nome da EmpresaEvolus Inc
Data de listagemFeb 08, 2018
CEOMr. David Moatazedi
Número de funcionários332
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 08
Endereço520 Newport Center Dr Ste 1200
CidadeNEWPORT BEACH
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92660-7022
Telefone19492844555
Sitehttps://www.evolus.com/
Código da empresaEOLS
Data de listagemFeb 08, 2018
CEOMr. David Moatazedi
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados